generic speaker image

Serban San-Marina

Founder/CEO | BiostatistiX

Toronto, ON, CANADA

Engaging speaker offering a new perspective on drug development

Industry Expertise (3)

Laboratory Services



Areas of Expertise (3)

Drug Mechanism of Action

Drug Development

Computational Drug Re-Profiling

Sample Talks (1)

Opportunities for Drug Re-Profiling in Spinal Cord Injury

Every year over 100,000 people world wide survive a traumatic spinal cord injury (SCI) but will require daily, life-long assistance. In Canada, over 30,000 people live with SCI at an annual cost of 1.5B. SCI is a complicated process involving interlinked events, such as activation of the immune system, apoptosis and excito-toxic damage. Individually, each of these events can be reversed by identifying and then disrupting the networks of interacting proteins that mediate the associated processes. Unfortunately, sequence-based high throughput approaches to identify small molecule inhibitors have had limited success. By contrast, the competing approach to re-profile existing drugs is gaining more popularity. The talk discusses approaches for drug re-profiling in spinal cord injury from the perspective of the lessons learned from recent developments in poly-target pharmacology.


  • Author Appearance